Export data to Excel for your own analysis. “Our most advanced program, ARCT-810, to treat ornithine transcarbamylase (OTC) deficiency, is currently being assessed in IND-enabling studies with the goal of filing an IND in the fourth quarter this year. Please log in to your account or sign up in order to add this asset to your watchlist. Winners and Losers, Small-cap ETFs set for their best month since the spring, CNBC’s Jim Cramer says the government’s latest ‘loser case’ could pay off in a big way for investors, Copper futures head for highest finish in over 2 years. Dive deeper with interactive charts and top stories of ARCTURUS THERAPEUTICS HOLDINGS INC.. Arcturus Therapeutics Ltd. (1566049) SEC Filing 10-K Annual report for the fiscal year ending Monday, December 31, 2018. Arcturus Therapeutics Holdings Inc. 0000899243-20-024363.pdf. Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q. Get SEC filings for Arcturus Therapeutics Ltd (ARCT), including Annual Report (10k) and Quarterly Report (10Q). View our full suite of financial calendars and market data tables, all for free. Nominated ARCT-810 as a clinical development candidate to treat OTC deficiency in January 2019. © American Consumer News, LLC dba MarketBeat® 2010-2020. On November 15, 2017, Alcobra Ltd. acquired Arcturus Therapeutics, Inc. (“Arcturus Inc.”) pursuant to a merger between the companies. For financial reporting, their fiscal year ends on December 31st. This page shows recent SEC filings related to Arcturus Therapeutics Ltd. Please wait while we load the requested 10-Q report or click the link below: https://last10k.com/sec-filings/report/1566049/000156459019018656/arct-10q_20190331.htm, Arcturus Therapeutics Ltd. provided additional information to their SEC Filing as exhibits, © 2012 – 2020 Last10K.com All Rights Reserved. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Highlighted multi-dose primate data (8 weekly doses @ 3 mg/kg, 24 mg/kg total in 50 days). Copyright © 2020 MarketWatch, Inc. All rights reserved. Get daily stock ideas top-performing Wall Street analysts. All quotes are in local exchange time. Arcturus Therapeutics Holdings Inc is primarely in the business of pharmaceutical preparations. Privacy Notice and Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. © 2020 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Over the course of 2019, we look forward to reporting on further developments in our pipeline and platform technologies.”, Advanced Flagship mRNA Program for Ornithine Transcarbamylase (OTC) Deficiency. Receive a free world-class investing education from MarketBeat. Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. 2018 Annual Report; PDF ; 2017 Annual Report; PDF ; About Arcturus Therapeutics Holdings Inc. 51-200 Employees. Dow up over 250 points, buoyed by signs fiscal stimulus talks making progress, Are you a stock investor with time and money? Here’s Why. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. Learn more. Arcturus therapeutics is a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. Learn everything you need to know about successful options trading with this three-part video course. Based in San Diego, California. If you reached this page by clicking a link on the MarketWatch site,please report it to Customer Service. Learn about financial terms, types of investments, trading strategies and more. The Investor Relations website contains information about Arcturus Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts. Work for Arcturus Therapeutics Holdings Inc.? Create an account, Condensed Consolidated Balance Sheets (Parenthetical), Condensed Consolidated Statements Of Operations And Comprehensive Loss, Condensed Consolidated Statements Of Stockholders' Equity, Condensed Consolidated Statements Of Cash Flows, Description Of Business, Basis Of Presentation And Summary Of Significant Accounting Policies, Description Of Business, Basis Of Presentation And Summary Of Significant Accounting Policies (Policies), Description Of Business, Basis Of Presentation And Summary Of Significant Accounting Policies (Tables), Description Of Business, Basis Of Presentation And Summary Of Significant Accounting Policies (Details Textual), Schedule Of Cash And Cash Equivalents And Restricted Cash (Details), Collaboration Revenue - Summary Of Changes In Balances Of Contract Assets And Contract Liability (Details), Collaboration Revenue (Details Textual 1), Balance Sheet Details - Schedule Of Prepaid Expenses And Other Current Assets (Details), Balance Sheet Details - Summary Of Components Of Property And Equipment, Net (Details), Balance Sheet Details - Schedule Of Accrued Liabilities (Details), Share-Based Compensation (Details Textual), Share-Based Compensation (Details 1) (Parenthetical), Leases - Payments Of Operating Lease Liability (Details), Related Party Transactions - Providence (Details Textual), Related Party Transactions - Equity-Method Investment (Details Textual), Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification, Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification, https://last10k.com/sec-filings/arct/0001564590-19-018656.htm. Looking for new stock ideas? Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Arcturus Therapeutics Provides Corporate Update and Reports Fourth Quarter and Year End 2018 Financial Results, “We are excited about the progress Arcturus is making in advancing our portfolio of RNA medicines which we are developing for liver disease, cystic fibrosis, genetic diseases and vaccine applications,” said Joseph Payne, President & CEO of Arcturus Therapeutics. Regulatory agencies in the U.S. and Europe have been informed of our CMC specifications along with our non-clinical and clinical design plans. Privacy Notice and Find the latest SEC Filings data for Arcturus Therapeutics Holdings Inc. Common Stock (ARCT) at Nasdaq.com. Arcturus Therapeutics Holdings Inc. has reached its limit for free report views. Arcturus’ commitment to the development of novel RNA therapeutics has led to collaborations with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, CureVac AG, Synthetic Genomics Inc., Duke-NUS, and the Cystic Fibrosis Foundation. Learn more. Identify stocks that meet your criteria using seven unique stock screeners. Key Opinion Leader (KOL) call in November 2018 on current treatment options for OTC Deficiency. Intraday data delayed at least 15 minutes or per exchange requirements. Intraday Data provided by FACTSET and subject to terms of use. Visit website. Archived Annual Reports. View ARCT's latest 10K form and other filings with the Securities and Exchange Commission at MarketBeat. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Reassumed 100% global rights for ARCT-810 in February 2019. Wall Street Is Learning to Love Caterpillar Stock. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. See what's happening in the market right now with MarketBeat's real-time news feed. Home SEC Filings Arcturus Therapeutics Ltd. ADR 10-K Annual Report Mon Mar 18 2019. Market Snapshot 30g non-GMP can be produced in less than a week. Safety Data – Dosing up to 7 mg/kg in mice. Historical and current end-of-day data provided by FACTSET. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Presented new data on our Ornithine Transcarbamylase (OTC) Deficiency program at the Leerink 8th Annual Global Healthcare Conference during Feb 27th-Mar 1st. Fundamental company data provided by Morningstar and Zacks Investment Research. View ARCT's latest 10K form and other filings with the Securities and Exchange Commission at MarketBeat. Arcturus mRNA Manufacturing capabilities have matured significantly. Arcturus remains on track to file an IND for ARCT-810 with the U.S. Food and Drug Administration (FDA) in 4Q 2019. All rights reserved. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. Dr. Pad Chivukula, Chief Scientific Officer of Arcturus Therapeutics, provided an overview of the company's ongoing LUNAR-OTC program. 10-K Annual Report. Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news. Do Not Sell My Information. Arcturus Therapeutics. Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.